Drug Profile
Antisense oligonucleotide Bcl-2 - ISIS
Alternative Names: Antisense Bcl-2 oligonucleotide - ISISLatest Information Update: 15 Jun 2007
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Vancouver General Hospital
- Class Antineoplastics; Nucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Sep 2002 Phase-I clinical trials in Cancer in Canada (unspecified route)
- 23 Nov 1999 Preclinical development for Cancer in Canada (Unknown route)